Explicit|04|04|332..336|2,1,1|also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||223..324|1|The move is sure to heighten concerns about increased Japanese investment in U.S. biotechnology firms|Inh|Null|Null|Null||||326..331;337..482|2,0;2,1,0;2,1,2;2,2|It is likely to bolster fears that the Japanese will use their foothold in U.S. biotechnology concerns to gain certain trade and competitive advantages|Inh|Null|Null|Null|||||||||
Explicit|04|04|746..750|4,1,1|then|||then|||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||486..546;600..730|3,0,0;3,0,1;3,0,2,0;3,0,2,1,0;3,0,2,1,1,0;3,0,2,1,1,1,0;3,0,2,1,1,1,1,0;3,0,2,1,1,1,1,1;3,0,3;3,1;3,2;3,3|Gen-Probe, an industry leader in the field of genetic probes last year signed an agreement for Chugai to exclusively market its diagnostic products in Japan for infectious diseases and cancer|Inh|Null|Null|Null||||732..745;751..808|4,0;4,1,0;4,1,2;4,2|Chugai agreed to fund certain associated research and development costs|Inh|Null|Null|Null||||548..598|3,0,2,1,1,1,1,2|which is a new technology used in diagnostic tests|||
Explicit|04|04|857..860|5,2|and|||and|||Expansion.Conjunction||||Wr|Comm|Null|Null||||812..855|5,0|That arrangement apparently has worked well|Inh|Null|Null|Null||||861..1091|5,3|Thomas A. Bologna, president and chief executive officer of Gen-Probe, founded in 1983, said the sale of the company means "we will be able to concentrate on running the business rather than always looking for sources of financing|Inh|Null|Null|Null|||||||||
EntRel|04|04||||1094|6|||||||||||||||812..1091|5|That arrangement apparently has worked well, and Thomas A. Bologna, president and chief executive officer of Gen-Probe, founded in 1983, said the sale of the company means "we will be able to concentrate on running the business rather than always looking for sources of financing||||||||1094..1208|6|Chugai agreed to pay $6.25 a share for Gen-Probe's 17.6 million common shares outstanding on a fully diluted basis|||||||||||||
Explicit|04|04|1319..1326|8,0,0|Because|||because|||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||1441..1604|8,1;8,2;8,3|the sale is sure to increase concerns that Japanese companies will buy American know-how and use it to obtain the upper hand in biotechnology trade and competition|Inh|Null|Null|Null||||1327..1440|8,0,1|the U.S. leads in most areas of biotechnology -- largely because of research investment by the U.S. government --|Inh|Null|Null|Null|||||||||
Implicit|04|04||||1760|10||as||Contingency.Cause.Reason||||Ot|Comm|Null|Null|1751..1759|10,0;10,1,0;10,2|He added|1609..1672|9,1|The biotechnology firms may be setting up their own competitors|Ot|Comm|Null|Null|1675..1749|9,0;9,2;9,3;9,4;9,5;9,6|said Richard Godown, president of the Industrial Biotechnology Association|1760..1855|10,1,1|that until now the Japanese have only acquired equity positions in U.S. biotechnology companies|Inh|Null|Null|Null|||||||||
Implicit|04|04||||1858|11||in other words||Expansion.Restatement.Equivalence||||Ot|Comm|Null|Null|1908..1915|11,0;11,2;11,3;11,4;11,5;11,6|he said|1760..1855|10,1,1|that until now the Japanese have only acquired equity positions in U.S. biotechnology companies|Ot|Comm|Null|Null|1751..1759|10,0;10,1,0;10,2|He added|1858..1905|11,1|They are piggybacking onto developed technology|Inh|Null|Null|Null|||||||||
Implicit|04|04||||1917|12||specifically||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||1858..1905|11,1|They are piggybacking onto developed technology|Ot|Comm|Null|Null|1908..1915|11,0;11,2;11,3;11,4;11,5;11,6|he said|1917..2041|12|During the past five years, Japanese concerns have invested in several of the U.S.'s 431 independent biotechnology companies|Inh|Null|Null|Null|||||||||
Implicit|04|04||||2043|13||specifically||Expansion.Instantiation||||Wr|Comm|Null|Null||||1917..2041|12|During the past five years, Japanese concerns have invested in several of the U.S.'s 431 independent biotechnology companies|Inh|Null|Null|Null||||2043..2268|13|Chugai has been one of the most active Japanese players in U.S. biotechnology companies; it has an equity investment in Genetics Institute Inc., Cambridge, Mass., and a joint-venture agreement with Upjohn Co., Kalamazoo, Mich|Inh|Null|Null|Null|||||||||
Implicit|04|04||||2132|13||for instance||Expansion.Instantiation||||Wr|Comm|Null|Null||||2043..2130|13,0|Chugai has been one of the most active Japanese players in U.S. biotechnology companies|Inh|Null|Null|Null||||2132..2268|13,2|it has an equity investment in Genetics Institute Inc., Cambridge, Mass., and a joint-venture agreement with Upjohn Co., Kalamazoo, Mich|Inh|Null|Null|Null|||||||||
Implicit|04|04||||2418|15||indeed||Expansion.Restatement.Generalization||||Ot|Comm|Null|Null|2493..2500|15,0;15,2;15,3;15,4;15,5,0;15,5,1;15,5,2;15,6|he said|2325..2415|14,2,1,1|that it wants 10% to 11% of its gross national product to come from biotechnology products|Ot|Comm|Null|Null|2272..2295;2314..2324|14,0;14,2,0;14,2,1,0;14,3|The Japanese government has stated|2418..2490|15,1|It is becoming more of a horse race every day between the U.S. and Japan|Inh|Null|Null|Null|||||||||
EntRel|04|04||||3285|19|||||||||||||||3103..3282|18|Osamu Nagayama, deputy president of Chugai, which spends about 15% of its sales on research and development, was unable to pinpoint how much money Chugai would pump into Gen-Probe||||||||3285..3423|19|We think Gen-Probe has technology important to people's health," he said, adding: "We think it is important for us to have such technology|||||||||||||
Implicit|04|04||||3456|20||in addition||Expansion.Conjunction||||Wr|Comm|Null|Null||||3377..3423|19,5,3,1,3,1,1|it is important for us to have such technology|Ot|PAtt|Null|Null|3368..3376|19,5,3,1,3,0;19,5,3,1,3,1,0|We think|3456..3606|20,1,1|that both companies would gain technological knowledge through the sale of Gen-Probe, which will expand "significantly" as a result of the acquisition|Ot|Comm|Null|Null|3426..3455|20,0;20,1,0;20,2|He and Mr. Bologna emphasized||||||
Implicit|04|04||||3684|22||by comparison||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||3610..3682|21|In 1988, Chugai had net income of $60 million on revenue of $991 million|Inh|Null|Null|Null||||3684..3750|22|GenProbe had a net loss of $9.5 million on revenue of $5.8 million|Inh|Null|Null|Null|||||||||
Implicit|04|04||||3752|23||however||Comparison.Concession.Contra-expectation||||Wr|Comm|Null|Null||||3684..3750|22|GenProbe had a net loss of $9.5 million on revenue of $5.8 million|Inh|Null|Null|Null||||3752..3951|23|Recently, Gen-Probe received a broad U.S. patent for a technology that helps detect, identify and quantify non-viral organisms through the targeting of a form of genetic material called ribosomal RNA|Inh|Null|Null|Null|||||||||
Explicit|04|04|4124..4128|25,0,1|also|||also|||Expansion.Conjunction||||Ot|Comm|Null|Null|4202..4218|25,1;25,2;25,3;25,4|Mr. Bologna said|3992..4113|24,3,1|that the sale will facilitate Gen-Probe's marketing of a diagnostic test for acquired immune deficiency syndrome, or AIDS|Ot|Comm|Null|Null|3955..3991|24,0;24,1;24,2;24,3,0;24,4|Among other things, Mr. Bologna said|4117..4123;4129..4200|25,0,0;25,0,2|Chugai will help Gen-Probe with its regulatory and marketing expertise in Asia|Inh|Null|Null|Null|||||||||
EntRel|04|04||||4220|26|||||||||||||||4117..4218|25|Chugai also will help Gen-Probe with its regulatory and marketing expertise in Asia, Mr. Bologna said||||||||4220..4310|26|The tender offer for Gen-Probe's shares is expected to begin next Monday, the company said|||||||||||||
